Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

6
101 Dividend Achievers Yield 2.8% To 9.7% For July

2018-07-14 seekingalpha
Dividend Achiever stocks are distinguished by 10 or more straight years of higher dividends. Some 266 Achiever equities are balanced by sector and capitalization. PFM is their tracking ETF.
IBM HEP TLP EPD SEP MCY TCP VGR APU PPL QCOM MO IVZ

6
101 Dividend Achievers Yield 2.8% To 9.7% For June

2018-07-13 seekingalpha
Dividend Achiever stocks are distinguished by 10 or more straight years of higher dividends. Some 266 Achiever equities are balanced by sector and capitalization. PFM is their tracking ETF.
IBM HEP TLP EPD SEP MCY TCP VGR APU PPL QCOM MO IVZ

9
Philip Morris (PM) Focused on RRPS, Inks Deal with Parallax

2018-06-29 zacks
Philip Morris International Inc. (PM - Free Report) has inked a deal with Parallax, in an attempt to move ahead with its strategy of expanding in the smoke-free products space. Canada-based Parallax, owned by leading pioneers in pulmonary research and medicine, provides low risk alternatives of tobacco. Both the companies will work towards reduction of harmful tobacco products by developing an effective nicotine-delivery system including e- cigarettes, pipe tobacco, cigars and hookah that leverages the most advanced technologies in pulmonary medicine.
PM VGR BATS 4162 PII MO

24
50 Consumer Defensive Sector Top Yield Stocks For June

2018-06-28 seekingalpha
British American Tobacco topped the June Consumer Defensive sector by analyst-estimated net gains for all top-yield stocks 6/26/18.
PM BUD CCLAF BATS 4162 DIDAY CUSI VGR CGUIF CCLAY CCL DIDAF AHBIF CGUSY MO

77
Global Recession Risk Rising

2018-06-27 seekingalpha
Global recession risk rises as both China and Europe warn of collateral damage from trade tariffs.
SOJA GEO EPR.PRG O.PRF CTL LTC BATS 4162 OPRF SUI.PRA VZA SUI MSCA HMNY ED MO GOV SO ARCC O MAIN RMR GOVNI ARU MSCA.CL VGR T ROKU CLDT VZ WPC OHI

67
Grow Your Income Even When Your Stocks Don't Increase The Dividend

2018-06-23 seekingalpha
There's a way we can give ourselves a raise, even when a company doesn't give us one.
SOJA GEO EPR.PRG O.PRF CTL LTC BATS 4162 OPRF SUI.PRA VZA SUI MSCA HMNY ED MO GOV SO ARCC O MAIN RMR GOVNI ARU MSCA.CL VGR SIR ROKU CLDT VZ WPC OHI

6
Smoking Hot Dividend Hike Coming From Altria

2018-06-22 seekingalpha
Altria (NYSE:MO) conjures up all kinds of nice feelings for me. It's pretty much everything I look for in a dividend growth stock: Juicy dividend, nice earnings growth, and consistent earnings growth. The only thing that stands in the way of it being a perfect company is that the tobacco business is a bit more risky than the regular consumer staples business.
IMBBY VGR ITYBF IMBBF MO

47
Castle Brands: Performance Remains Solid, Valuation Remains A Question Mark

2018-06-19 seekingalpha
Castle Brands posted a nice FY18, as growth in the core whiskey and ginger beer categories continues.
STZ.B VGR RCO REMYY STZ ROX REMYF

10
Can RRPS, Pricing Aid Revival at Phillip Morris (PM) Stock?

2018-06-19 zacks
Philip Morris International Inc. (PM - Free Report) continues to be whipped by regulatory hurdles surrounding the tobacco industry, which along with rising health consciousness have been denting Phillip Morris’ cigarette volumes. This has caused a 19.3% decline in the company’s shares in the past three months, wider than the industry’s decline of 13%. Nevertheless, the company’s reduced risk products (RRPs) category has been gaining traction, which should help it cushion the stock.
PM VGR BATS 4162 RAI MO

390
Is Vector Group Dividend For Real?

2018-06-18 seekingalpha
The company’s business model consists of investing the proceeds from their discount cigarette business into a high-end real estate business.
VGR O.PRF O XXII OPRF MO

63
Will Rising Rates Derail This 11.95% Yielding REIT?

2018-06-16 seekingalpha
The Fed Chair is very sanguine on the outlook for the U.S. economy going forward, supporting his intent to proffer two more raises this year.
SOJA GEO EPR.PRG O.PRF CTL LTC BATS 4162 OPRF SUI.PRA VZA SUI MSCA HMNY ED MO GOV SO ARCC O MAIN RMR GOVNI ARU MSCA.CL VGR ROKU CLDT VZ WPC OHI

64
Top Consumer Company Near 52-Week Low Yields 5.89%: Seeks Redemption In India

2018-06-13 seekingalpha
Anyone paying even the least amount of attention to the tobacco industry is cognizant of the fact that Philip Morris (PM) is putting a full-court press on getting its IQOS smokeless product to surpass, supplant and replace tobacco products like cigarettes.
SOJA PM GEO EPR.PRG O.PRF CTL LTC BATS 4162 OPRF SUI.PRA VZA SUI MSCA HMNY ED MO GOV SO ARCC O MAIN RMR GOVNI ARU MSCA.CL VGR NDAQ ROKU CLDT VZ WPC OHI

56
Little Rocket Man: 'Great Personality'!

2018-06-13 seekingalpha
When sanity and reality returns, investors will flock back into the likes of Boeing, Raytheon and Lockheed Martin for safety, capital appreciation and income.
SOJA LMT GEO EPR.PRG O.PRF CTL LTC BATS 4162 OPRF SUI.PRA VZA SUI MSCA ED MO GOV SO ARCC O MAIN RMR GOVNI ARU MSCA.CL VGR ROKU CLDT VZ WPC OHI

1
Vector Group: Look Ma, No Hands

2018-06-12 seekingalpha
Vector Group pays a $0.40 quarterly dividend that can be challenging to figure out how they afford.
DUKH VGR DUK

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

8h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

9h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to VGR / Vector Group, Ltd. on message board site Silicon Investor.

Covalent Group Inc (CVGR) an undiscovered CRO
CUSIP: 92240M108